http://ukccfkn.cn/en/2020/12/10/biogen-files-new-drug-application-for-aducanumab-in-japan/2021-04-12T13:40:01+08:00http://ukccfkn.cn/en/2020/11/30/eisai-to-present-latest-data-on-perampanel-at-the-74th-american-epilepsy-society-annual-meeting/2021-04-12T13:40:51+08:00http://ukccfkn.cn/en/2020/11/30/eisai-and-wren-therapeutics-enter-into-research-collaboration-agreement-for-drug-discovery-for-synucleinopathies/2021-04-12T13:42:29+08:00http://ukccfkn.cn/en/2021/02/08/mission%e3%80%81vision%e3%80%81value-2/2023-04-10T16:17:49+08:00http://ukccfkn.cn/en/2020/11/27/abbvie-and-eisai-announce-an-approval-for-additional-indication-of-humira-a-fully-human-anti-tnf%ce%b1-monoclonal-antibody-for-the-treatment-of-pyoderma-gangrenosum-for-the-first-time-in-the-w/2021-04-12T13:48:49+08:00http://ukccfkn.cn/en/2021/02/08/culture-of-eisai-china/2023-11-29T13:00:50+08:00http://ukccfkn.cn/en/2020/11/26/eisai-commences-padico-smartphone-application-service-in-japan-to-support-the-daily-lives-of-patients-with-parkinsons-disease/2021-04-12T13:49:01+08:00http://ukccfkn.cn/en/2020/11/18/jyseleca-filgotinib-for-rheumatoid-arthritis-launches-in-japan/2021-04-12T13:35:50+08:00http://ukccfkn.cn/en/2020/11/18/eisai-selected-for-membership-in-dow-jones-sustainability-asia-pacific-index-2020-for-seventh-time/2021-04-12T13:51:28+08:00http://ukccfkn.cn/en/2021/02/08/compliance/2023-06-06T10:09:28+08:00http://ukccfkn.cn/en/2021/02/08/csr-2/2024-05-21T12:39:47+08:00http://ukccfkn.cn/en/2021/02/08/jobs/2021-05-15T14:48:33+08:00http://ukccfkn.cn/en/2021/02/08/about-eisai-china/2021-02-08T13:01:57+08:00http://ukccfkn.cn/en/2021/02/08/presidents-message/2026-06-16T18:09:59+08:00http://ukccfkn.cn/en/2021/02/08/company-profile/2026-04-07T13:27:38+08:00http://ukccfkn.cn/en/2021/02/08/commitment-to-environmental-protection/2022-04-24T16:46:49+08:00http://ukccfkn.cn/en/2021/02/08/quality-assurance/2021-04-22T20:04:15+08:00http://ukccfkn.cn/en/2021/02/08/manufacturing/2022-04-24T16:43:02+08:00http://ukccfkn.cn/en/2021/02/08/history/2022-06-21T10:13:39+08:00http://ukccfkn.cn/en/2021/02/19/%e9%9a%90%e7%a7%81%e6%94%bf%e7%ad%96-en/2021-03-31T11:50:12+08:00http://ukccfkn.cn/en/2021/02/19/%e6%b3%95%e5%be%8b%e5%85%ac%e5%91%8a-en/2021-03-31T12:08:16+08:00http://ukccfkn.cn/en/2021/02/19/%e5%8f%af%e7%94%a8%e6%80%a7-en/2021-09-02T16:29:10+08:00http://ukccfkn.cn/en/2021/02/23/%e8%81%94%e7%b3%bb%e6%88%91%e4%bb%ac-en/2026-04-07T13:09:42+08:00http://ukccfkn.cn/en/2021/02/24/%e5%85%b3%e4%ba%8e%e5%8d%ab%e6%9d%90%e4%b8%ad%e5%9b%bd-2/2026-05-21T19:58:07+08:00http://ukccfkn.cn/en/2021/02/25/%e5%af%bb%e6%b1%82%e5%90%88%e4%bd%9c-en/2021-03-18T16:01:25+08:00http://ukccfkn.cn/en/2021/02/26/%e5%af%bb%e6%b1%82%e5%90%88%e4%bd%9c%e7%bb%a7%e7%bb%ad-en/2021-04-16T11:24:15+08:00http://ukccfkn.cn/en/2020/11/10/lenvima-plus-keytruda-demonstrated-statistically-significant-improvement-in-progression-free-survival-overall-survival-and-objective-response-rate-versus-sunitinib-as-first-line-treatment/2021-03-18T08:47:33+08:00http://ukccfkn.cn/en/2019/12/09/sysmex-presents-academic-report-with-a-view-to-creating-a-simple-method-of-diagnosing-alzheimers-disease-using-blood/2021-03-18T08:51:17+08:00http://ukccfkn.cn/en/2020/10/30/european-medicines-agency-accepts-biogens-aducanumab-marketing-authorization-application-for-alzheimers-disease/2021-03-18T08:54:07+08:00http://ukccfkn.cn/en/2020/10/28/eisai-to-present-latest-data-on-pipeline-assets-in-the-area-of-alzheimers-disease-and-dementia-at-the-13th-clinical-trials-on-alzheimers-disease-conference/2022-03-11T13:56:31+08:00http://ukccfkn.cn/en/2020/10/27/global-coalition-for-adaptive-research-amgen-and-eisai-announce-first-patient-enrolled-in-international-covid-19-trial/2021-03-18T09:05:10+08:00http://ukccfkn.cn/en/2020/10/26/eisai-and-cogstate-expand-agreement-for-global-development-and-commercialization-of-digital-cognitive-assessment-technologies/2021-03-18T09:14:09+08:00http://ukccfkn.cn/en/2020/10/21/notice-regarding-biogens-disclosure-about-the-submission-of-marketing-authorization-application-to-european-medicines-agency-for-aducanumab-for-alzheimers-disease/2021-03-18T09:15:51+08:00http://ukccfkn.cn/en/2020/10/16/supplementary-new-drug-applications-for-anti-epileptic-drug-fycompa-as-monotherapy-for-partial-onset-seizures-pediatric-indication-for-partial-onset-seizures-accepted-in-china/2021-03-18T09:25:05+08:00http://ukccfkn.cn/en/2020/10/08/the-university-of-tokyo-and-eisai-announce-research-collaboration-for-the-development-and-drug-discovery-of-targeted-protein-degradation-technology/2021-03-18T09:33:28+08:00http://ukccfkn.cn/en/2020/10/06/industry-academia-government-joint-development-agreement-aiming-for-drug-discovery-for-covid-19-utilizing-eritoran-and-e6011-concluded-non-clinical-research-activities-commence/2021-03-18T09:36:21+08:00http://ukccfkn.cn/en/2020/09/30/eisai-and-seikagaku-enter-into-agreement-for-the-marketing-alliance-of-si-613-a-treatment-of-osteoarthritis-in-south-korea/2021-03-18T09:40:13+08:00http://ukccfkn.cn/en/2020/09/25/jyseleca-filgotinib-approved-in-japan-for-rheumatoid-arthritis/2022-03-11T13:18:01+08:00http://ukccfkn.cn/en/2020/09/23/eisai-receives-positive-opinion-from-emas-chmp-on-use-of-antiepileptic-agent-fycompa-in-pediatric-patients/2021-03-18T09:44:04+08:00http://ukccfkn.cn/en/2020/09/23/eisai-and-merck-present-first-time-data-from-two-studies-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-seven-different-tumor-types-at-esmo-virtual-congress-2020/2021-03-18T09:46:03+08:00http://ukccfkn.cn/en/2020/09/20/eisai-china-inc-successfully-held-2020-ads-summit/2021-08-24T17:23:37+08:00http://ukccfkn.cn/en/2020/09/18/eisai-presents-latest-data-of-phase-i-clinical-trial-on-liposomal-formulation-of-anti-cancer-agent-halaven-eribulin-at-esmo-virtual-congress-2020/2021-03-18T09:52:17+08:00http://ukccfkn.cn/en/2020/09/11/eisai-to-present-abstracts-on-oncology-products-and-pipeline-at-esmo-virtual-congress-2020/2021-03-18T09:53:53+08:00http://ukccfkn.cn/en/2020/09/07/eisai-to-take-over-manufacturing-and-marketing-approval-for-equfina-50mg-tablets-safinamide-mesilate-in-japan-from-meiji-seika-pharma/2022-03-11T12:23:50+08:00http://ukccfkn.cn/en/2020/09/02/eisai-china-wins-greater-suzhou-best-employer-award-for-four-consecutive-years/2021-03-18T10:00:47+08:00http://ukccfkn.cn/en/2020/09/01/promote-development-of-core-philosophy-of-eisai-the-second-hhc-summit-of-eisai-china/2021-03-18T10:05:00+08:00http://ukccfkn.cn/en/2020/08/30/eisai-china-shortlisted-for-top-100-pharmaceutical-enterprises-in-china-for-five-consecutive-years/2021-03-18T10:06:28+08:00http://ukccfkn.cn/en/2020/08/25/relieving-discomfort-caused-by-dry-skin-with-the-moisturizing-effect-of-pharmaceutical-care-products-eisai-to-launch-sahne-medical-spray-and-sahne-medical-cream/2021-03-18T10:08:34+08:00http://ukccfkn.cn/en/2020/08/25/eisai-to-present-latest-data-of-lemborexant-at-34th-annual-sleep-meeting-sleep2020/2022-03-11T14:00:20+08:00http://ukccfkn.cn/en/2020/07/30/application-for-additional-indication-of-anti-cancer-agent-lenvima-for-unresectable-thymic-carcinoma-submitted-in-japan/2021-03-18T10:17:20+08:00http://ukccfkn.cn/en/2020/07/28/eisai-and-dena-to-provide-smartphone-app-easiit-app-through-business-alliance-agreement/2021-03-18T10:19:52+08:00http://ukccfkn.cn/en/2020/07/20/smartphone-app-for-vital-signs-measurement-of-patients-with-the-novel-coronavirus-infection-experimental-study-project-adopted-as-amed-project/2021-03-18T10:22:34+08:00http://ukccfkn.cn/en/2020/07/14/initiation-of-new-phase-iii-clinical-study-ahead-3-45-of-ban2401-preclinical-asymptomatic-alzheimers-disease/2021-03-18T10:24:23+08:00http://ukccfkn.cn/en/2020/07/10/industry-academia-government-joint-development-agreement-aiming-for-drug-discovery-for-systemic-lupus-erythematosus-by-practical-application-of-toll-like-receptor-research-concluded/2021-03-18T10:26:42+08:00http://ukccfkn.cn/en/2020/07/06/new-fine-granule-formulation-of-anti-epileptic-drug-fycompa-launched-in-japan/2021-03-18T10:28:51+08:00http://ukccfkn.cn/en/2020/06/25/eisai-receives-approval-for-parkinsons-disease-treatment-equfina-in-south-korea/2022-03-11T14:02:50+08:00http://ukccfkn.cn/en/2020/06/02/eisai-launches-new-insomnia-drug-dayvigo-lemborexant-civ-in-the-united-states-as-a-treatment-option-for-adults-with-insomnia/2021-03-18T10:32:21+08:00http://ukccfkn.cn/en/2020/05/29/abbvie-and-eisai-announce-an-approval-for-partial-changes-in-the-marketing-approval-of-humira-a-fully-human-anti-tnf%ce%b1-monoclonal-antibody-concerning-the-dosage-and-administration-related/2021-03-18T10:33:33+08:00http://ukccfkn.cn/en/2020/05/14/eisai-to-present-data-on-oncology-pipeline-and-products-at-asco-annual-meeting/2021-03-18T10:35:12+08:00http://ukccfkn.cn/en/2020/04/27/eisai-selected-as-most-honored-company-and-the-first-place-of-the-sector-in-the-all-japan-executive-team-best-ir-company-ranking-by-institutional-investor-magazine/2021-03-18T10:37:30+08:00http://ukccfkn.cn/en/2020/04/01/eisai-and-seikagaku-enter-into-agreement-for-the-co-development-and-marketing-alliance-of-si-613-a-treatment-of-osteoarthritis-in-china/2021-03-18T10:41:47+08:00http://ukccfkn.cn/en/2020/03/27/the-6th-eisai-chinas-give-forum-webinar-held-successfully/2021-03-18T10:43:50+08:00http://ukccfkn.cn/en/2020/03/26/eisai-submits-marketing-authorization-application-in-japan-for-anticancer-agent-denileukin-diftitox-genetic-recombinant-for-cutaneous-t-cell-lymphoma-and-peripheral-t-cell-lymphoma/2021-03-18T10:45:11+08:00http://ukccfkn.cn/en/2020/03/22/2020-eisai-empowering-neurologys-future-summit-online-kicks-off/2021-03-18T10:47:53+08:00http://ukccfkn.cn/en/2020/03/02/eisai-china-escorts-you-to-tide-over-the-crisis/2021-03-18T10:52:27+08:00http://ukccfkn.cn/en/2020/02/25/eisai-and-fuji-yakuhin-conclude-license-agreement-concerning-the-development-and-distribution-of-dotinurad-a-treatment-for-hyperuricemia-and-gout-in-china/2021-03-18T10:53:51+08:00http://ukccfkn.cn/en/2020/02/21/eisai-receives-the-presidents-award-of-the-japan-techno-economics-society-at-the-8th-technology-management-and-innovation-awards/2021-03-18T10:55:43+08:00http://ukccfkn.cn/en/2020/01/10/launch-of-anticancer-agent-halaven-in-china/2021-03-18T10:59:01+08:00http://ukccfkn.cn/en/2020/01/06/fycompa-for-adjunctive-treatment-of-partial-onset-seizures-launched-in-china/2021-03-18T11:02:27+08:00http://ukccfkn.cn/en/2019/12/23/u-s-fda-approves-eisais-dayvigo-lemborexant-for-treatment-of-insomnia-in-adult-patients/2021-03-18T11:04:03+08:00http://ukccfkn.cn/en/2019/12/09/sysmex-presents-academic-report-with-a-view-to-creating-a-simple-method-of-diagnosing-alzheimers-disease-using-blood-2/2021-03-18T13:09:33+08:00http://ukccfkn.cn/en/2019/12/05/eisai-to-present-new-research-on-eribulin-halaven-at-42nd-annual-san-antonio-breast-cancer-symposium/2021-03-18T13:13:50+08:00http://ukccfkn.cn/en/2019/12/02/eisai-to-present-latest-data-on-alzheimers-disease-dementia-pipeline-at-12th-clinical-trials-on-alzheimers-disease-conference/2021-03-18T13:15:45+08:00http://ukccfkn.cn/en/2019/12/02/additional-indication-for-lenvima-lenvatinib-for-differentiated-thyroid-cancer-accepted-in-china/2021-03-18T13:16:37+08:00http://ukccfkn.cn/en/2019/12/02/eisai-china-inc-is-certified-as-the-top-employers-china-2020/2021-03-18T13:19:16+08:00http://ukccfkn.cn/en/2019/12/01/launch-meeting-of-the-third-generation-antiepileptic-drug-of-fycompa-perampanel-in-china/2021-03-18T13:21:02+08:00http://ukccfkn.cn/en/2019/11/26/eisai-china-pharmaceutical-co-ltd-carried-out-scholarships-and-grants-program-in-peking-university-health-science-center-for-8-consecutive-years/2021-03-18T13:23:09+08:00http://ukccfkn.cn/en/2019/11/26/eisai-to-present-latest-data-on-perampanel-at-73rd-american-epilepsy-society-annual-meeting/2021-03-18T13:24:16+08:00http://ukccfkn.cn/en/2019/11/05/eisai-transfers-rights-to-receive-royalties-outside-of-japan-for-ezh2-inhibitor-tazemetostat-to-royalty-pharma/2021-03-18T13:27:12+08:00http://ukccfkn.cn/en/2019/10/22/biogen-plans-regulatory-filing-for-aducanumab-in-alzheimers-disease-based-on-new-analysis-of-larger-dataset-from-phase-3-studies/2021-03-18T13:28:40+08:00http://ukccfkn.cn/en/2019/10/19/eisai-china-successfully-held-2019-ads-beijing/2021-03-18T13:31:20+08:00http://ukccfkn.cn/en/2019/10/15/new-drug-approval-for-fycompa-for-adjunctive-treatment-of-partial-onset-seizures-in-china/2021-03-18T13:33:23+08:00http://ukccfkn.cn/en/2019/10/13/eisai-china-inc-actively-participated-in-the-2nd-large-scale-alzheimer-disease-month-memory-walk-campaign/2021-03-18T13:35:36+08:00http://ukccfkn.cn/en/2019/09/30/eisai-and-nichi-iko-enter-into-collaboration-agreement-for-generic-pharmaceutical-business-in-china/2021-03-18T13:36:47+08:00http://ukccfkn.cn/en/2019/09/26/eisai-and-fronteo-to-launch-coroban-tumbling-and-falling-prediction-system-for-inpatients/2021-04-12T14:46:45+08:00http://ukccfkn.cn/en/2019/09/24/eisai-to-present-abstracts-on-oncology-products-and-pipeline-at-esmo-2019-congress/2021-03-18T13:40:42+08:00http://ukccfkn.cn/en/2019/09/20/eisai-and-meiji-announce-parkinsons-disease-treatment-equfina-tablets-safinamide-mesilate-approved-in-japan/2021-03-18T13:41:43+08:00http://ukccfkn.cn/en/2019/09/19/eisai-to-present-latest-data-on-lemborexant-at-world-sleep-congress/2021-03-18T13:53:05+08:00http://ukccfkn.cn/en/2019/09/18/fda-approves-lenvima-lenvatinib-plus-keytruda-pembrolizumab-combination-treatment-for-patients-with-certain-types-of-endometrial-carcinoma/2021-03-18T13:54:40+08:00http://ukccfkn.cn/en/2019/09/18/eisai-selected-for-membership-in-dow-jones-sustainability-asia-pacific-index-2019-for-sixth-time/2021-03-18T13:56:29+08:00http://ukccfkn.cn/en/2019/09/17/eisai-receives-iia-japan-chairmans-award-of-institute-of-internal-auditors-japan/2021-03-18T13:57:58+08:00http://ukccfkn.cn/en/2019/08/28/eisai-enters-into-business-alliance-with-cogstate-for-exclusive-development-and-commercialization-of-a-digital-tool-for-self-assessment-of-cognitive-function-in-japan/2021-03-18T14:00:06+08:00http://ukccfkn.cn/en/2019/08/27/eisai-provides-tanks-to-supply-clean-water-to-neglected-tropical-diseases-endemic-regions-in-kenya-in-collaboration-with-merck/2021-03-18T14:02:00+08:00http://ukccfkn.cn/en/2019/08/07/eisai-china-inc-participates-in-cpc-sub-branch-co-construction-campaign-in-zhenping/2021-03-18T14:04:28+08:00http://ukccfkn.cn/en/2019/07/23/eisai-and-merck-co-inc-kenilworth-n-j-u-s-a-receive-breakthrough-therapy-designation-from-fda-for-lenvima-lenvatinib-plus-keytruda-pembrolizumab-combination-treatment/2021-03-18T14:07:02+08:00http://ukccfkn.cn/en/2019/07/19/latest-trends-of-treatment-for-alzheimers-disease-in-sessions-and-symposium-at-alzheimers-association-international-conference-aaic-2019/2021-03-18T14:09:19+08:00http://ukccfkn.cn/en/2019/07/19/latest-trends-of-treatment-for-alzheimers-disease-in-sessions-and-symposium-at-alzheimers-association-international-conference-aaic-2019-2/2021-03-18T14:12:17+08:00http://ukccfkn.cn/en/2019/07/18/eisai-presents-research-evaluating-correlation-of-highly-precisely-measured-amyloid-beta-in-plasma-and-cerebrospinal-fluid-with-newly-developed-automated-protein-assay-system-at-alzheimers-as/2021-03-18T14:14:28+08:00http://ukccfkn.cn/en/2019/07/18/eisai-presents-nonclinical-research-results-of-elenbecestat-of-without-significant-effects-on-synaptic-function-in-brain-by-spinal-densitiy-evaluation-at-effective-dose-to-decrease-amyloid-beta-level/2021-03-18T14:16:36+08:00http://ukccfkn.cn/en/2019/07/17/anticancer-agent-eribulin-mesylate-approved-for-treatment-of-locally-advanced-or-metastatic-breast-cancer-in-china/2021-04-12T14:44:26+08:00http://ukccfkn.cn/en/2019/07/11/eisai-listed-for-18th-consecutive-year-in-ftse4good-index-series-an-index-for-socially-responsible-investment/2021-03-18T14:21:52+08:00http://ukccfkn.cn/en/2019/07/10/eisai-center-for-genetics-guided-dementia-discovery-commences-full-scale-operation-toward-innovative-dementia-treatments-with-new-drug-discovery-approach-in-cambridge-massachusetts/2021-03-18T14:24:43+08:00http://ukccfkn.cn/en/2019/07/03/donate-350000-yuan-again-to-help-the-elderly-with-cognitive-impairment-go-home/2021-03-18T14:26:40+08:00http://ukccfkn.cn/en/2019/06/24/eisai-china-supports-health-to-countryside-project-for-six-consecutive-years/2021-03-18T14:27:55+08:00http://ukccfkn.cn/en/2019/06/17/total-synthesis-and-nonclinical-study-results-of-a-novel-anticancer-drug-candidate-e7130-derived-from-total-synthesis-of-halichondrin-found-in-joint-research-between-eisai-and-harvard-university-scien/2021-03-18T14:29:44+08:00http://ukccfkn.cn/en/2019/06/14/eisai-to-present-latest-data-on-perampanel-at-33rd-international-epilepsy-congress/2021-03-18T14:31:28+08:00http://ukccfkn.cn/en/2019/05/29/eisai-to-present-latest-data-on-lemborexant-including-integrated-analysis-of-phase-iii-clinical-studies-at-33rd-annual-sleep-meeting/2021-03-18T14:33:18+08:00http://ukccfkn.cn/en/2019/05/16/eisai-to-present-data-on-oncology-pipeline-and-products-at-55th-asco-annual-meeting/2021-03-18T14:39:28+08:00http://ukccfkn.cn/en/2019/05/01/eisai-buys-out-purdue-rights-to-end-collaboration/2021-03-18T14:40:35+08:00http://ukccfkn.cn/en/2019/04/24/eisai-to-present-latest-data-on-lemborexant-and-perampanel-at-annual-american-academy-of-neurology-meeting/2021-03-18T14:42:34+08:00http://ukccfkn.cn/en/2019/03/29/data-safety-monitoring-board-recommends-continuation-of-phase-iii-clinical-studies-of-bace-inhibitor-elenbecestat-in-early-alzheimers-disease/2021-03-18T14:44:01+08:00http://ukccfkn.cn/en/2019/03/22/initiation-of-phase-iii-clinical-trial-of-ban2401-in-early-alzheimers-disease/2021-03-18T14:45:19+08:00http://ukccfkn.cn/en/2019/03/12/eisai-and-imbrium-therapeutics-announce-u-s-fda-filing-acceptance-of-new-drug-application-for-lemborexant-for-the-treatment-of-insomnia/2021-03-18T14:48:19+08:00http://ukccfkn.cn/en/2019/02/13/eisai-submits-application-in-europe-seeking-approval-for-fycompa-as-treatment-for-pediatric-patients-with-epilepsy/2021-03-18T14:50:27+08:00http://ukccfkn.cn/en/2019/02/04/total-synthesis-and-nonclinical-study-results-of-a-novel-anticancer-drug-candidate-e7130-derived-from-total-synthesis-of-halichondrin-found-in-joint-research-between-eisai-and-harvard-university-sci-2/2021-03-18T14:59:33+08:00http://ukccfkn.cn/en/2019/01/30/supplementary-new-drug-application-submitted-in-japan-for-fycompa-as-monotherapy-for-partial-onset-seizures-pediatric-indication-for-partial-onset-seizures-as-well-as-new-formulation/2021-03-18T15:01:08+08:00http://ukccfkn.cn/en/2019/01/22/eisai-listed-as-a-global-100-most-sustainable-corporation-for-the-fourth-time/2021-03-18T15:02:49+08:00http://ukccfkn.cn/en/2019/01/12/2019-lenvatinib-launching-ceremony-jointly-held-by-eisai-china-and-msd-china/2021-03-18T15:10:38+08:00http://ukccfkn.cn/en/2019/01/04/new-drug-application-for-perampanel-designated-for-priority-review-by-china-national-medical-products-administration-for-adjunctive-treatment-of-partial-onset-seizures/2022-03-11T15:31:53+08:00http://ukccfkn.cn/en/2018/11/27/11%e6%9c%8827%e6%97%a5%ef%bc%8c%e9%9a%8f%e7%9d%80%e4%b8%ad%e5%9b%bd%e5%8c%bb%e7%a7%91%e5%a4%a7%e5%ad%a62017-2018%e5%b9%b4%e5%ba%a6%e6%9c%ac%e7%a7%91%e7%94%9f%e5%85%88%e8%bf%9b%e9%9b%86%e4%bd%93/2021-04-12T14:17:30+08:00http://ukccfkn.cn/en/2018/11/22/eisai-to-present-latest-data-on-perampanel-at-72nd-american-epilepsy-society-annual-meeting/2021-03-18T15:20:58+08:00http://ukccfkn.cn/en/2018/11/12/eisai-launches-lenvima-lenvatinib-in-china/2022-03-11T14:43:19+08:00http://ukccfkn.cn/en/2018/11/07/eisai-china-commences-full-scale-operation-of-new-suzhou-plant/2021-03-18T15:31:24+08:00http://ukccfkn.cn/en/2018/10/27/eisai-china-inc-held-the-2018-ads/2021-03-18T15:33:37+08:00http://ukccfkn.cn/en/2018/10/26/eisai-presents-new-data-on-lemborexant-for-treatment-of-irregular-sleep-wake-rhythm-disorder-in-patients-with-alzheimers-disease-at-the-11th-clinical-trials-in-alzheimers-disease-con/2021-03-18T15:38:29+08:00http://ukccfkn.cn/en/2018/10/25/eisai-and-biogen-announce-presentation-of-additional-data-from-the-phase-ii-clinical-trial-of-ban2401-in-early-alzheimers-disease-at-the-2018-clinical-trials-on-alzheimers-disease-c/2021-03-18T15:39:59+08:00http://ukccfkn.cn/en/2018/10/23/eisai-china-donates-approximately-rmb2-5-million-yuan-worth-of-medicines-to-the-health-to-countryside-project-for-five-consecutive-years/2021-03-18T15:41:52+08:00http://ukccfkn.cn/en/2018/10/18/eisai-to-present-latest-data-on-alzheimers-disease-dementia-pipeline-at-11th-clinical-trials-on-alzheimers-disease-conference/2021-03-18T16:14:26+08:00http://ukccfkn.cn/en/2018/10/17/eisai-and-purdue-pharma-announce-positive-topline-results-of-sunrise-2-the-second-phase-3-pivotal-study-of-lemborexant/2021-03-18T16:15:46+08:00http://ukccfkn.cn/en/2018/10/12/new-drug-application-for-perampanel-for-adjunctive-treatment-of-partial-onset-seizures-accepted-in-china/2022-03-11T14:45:41+08:00http://ukccfkn.cn/en/2018/09/05/eisai-and-merck-co-inc-kenilworth-n-j-u-s-a-announce-china-national-medical-products-administration-nmpa-approval-of-lenvima-lenvatinib-for-treatment-of-unresectable-hepatocellular/2022-03-11T14:30:17+08:00http://ukccfkn.cn/en/2018/08/29/lenvima-lenvatinib-capsules-approved-for-first-line-treatment-of-unresectable-hepatocellular-carcinoma-hcc-in-south-korea/2022-03-11T14:53:51+08:00http://ukccfkn.cn/en/2018/08/28/long-term-cardiovascular-outcomes-data-for-anti-obesity-agent-belviq-presented-at-the-european-society-of-cardiology-and-published-in-the-new-england-journal-of-medicine/2021-03-18T16:25:23+08:00http://ukccfkn.cn/en/2018/08/23/european-commission-grants-marketing-authorization-for-lenvima-lenvatinib-as-first-line-treatment-in-adults-with-advanced-or-unresectable-hepatocellular-carcinoma/2022-03-11T15:39:14+08:00http://ukccfkn.cn/en/2018/08/22/eisai-china-inc-awarded-great-suzhou-best-employer-for-second-consecutive-years/2021-03-18T16:27:55+08:00http://ukccfkn.cn/en/2018/08/17/eisai-and-merck-co-inc-kenilworth-n-j-u-s-a-announce-fda-approval-of-lenvima-lenvatinib-capsules-for-first-line-treatment-of-unresectable-hepatocellular-carcinoma-hcc/2022-03-11T15:55:45+08:00http://ukccfkn.cn/en/2018/08/04/eisai-china-listed-for-the-third-consecutive-year-in-china-top-100-pharmaceutical-companies/2021-03-18T16:31:09+08:00http://ukccfkn.cn/en/2018/07/31/eisai-signs-collaboration-agreement-for-anti-obesity-agent-lorcaserin-in-china-to-cy-biotech/2022-03-11T13:44:09+08:00http://ukccfkn.cn/en/2018/07/31/eisai-and-merck-co-inc-kenilworth-n-j-u-s-a-announce-u-s-fda-grants-breakthrough-therapy-designation-for-lenvima-in-combination-with-keytruda/2022-03-11T15:43:54+08:00http://ukccfkn.cn/en/2018/07/26/eisai-and-biogen-announce-detailed-results-of-phase-ii-clinical-study-of-ban2401-in-early-alzheimers-disease-at-alzheimers-association-international-conference-aaic-2018/2021-03-19T09:18:51+08:00http://ukccfkn.cn/en/2018/07/19/latest-data-on-eisais-alzheimers-disease-dementia-pipeline-to-be-presented-at-alzheimers-association-international-conference-aaic-2018/2021-03-19T09:21:25+08:00http://ukccfkn.cn/en/2018/06/21/abbvie-and-eisai-announce-the-launch-of-humira-for-subcutaneous-injection-20-mg-syringe-0-2-ml-a-new-pediatric-formulation-of-humira/2021-03-19T11:37:14+08:00http://ukccfkn.cn/en/2018/06/20/join-hands-to-make-a-win-win-situation-eisai-china-launches-its-first-liver-reserve-function-testing-device-in-china-market/2021-03-19T09:29:20+08:00http://ukccfkn.cn/en/2018/06/04/eisai-and-merck-co-inc-kenilworth-n-j-u-s-a-announce-data-at-2018-asco-annual-meeting-from-investigational-studies-of-lenvima-and-keytruda-combination-therapy-in-four-different-t/2021-03-19T09:32:54+08:00http://ukccfkn.cn/en/2018/05/31/u-s-fda-designates-for-priority-review-eisais-supplemental-new-drug-application-for-antiepileptic-drug-fycompa-as-treatment-for-pediatric-patients-with-epilepsy/2021-03-19T09:35:26+08:00http://ukccfkn.cn/en/2018/05/29/eisai-china-won-the-best-hr-teams-in-greater-china-of-hroot-awards-2018/2021-03-19T10:15:03+08:00http://ukccfkn.cn/en/2018/04/26/the-eisai-china-scholarships-program-supports-chinas-education-for-18-consecutive-years/2021-03-19T10:20:15+08:00http://ukccfkn.cn/en/2018/04/19/worlds-first-bile-acid-transporter-inhibitor-goofice-5mg-tablet-launched-in-japan/2021-03-19T10:22:51+08:00http://ukccfkn.cn/en/2018/04/02/eisai-submits-supplemental-new-drug-application-to-u-s-fda-for-fycompa-as-treatment-for-pediatric-patients-with-epilepsy/2021-03-19T10:23:58+08:00http://ukccfkn.cn/en/2018/03/23/anticancer-agent-lenvima-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc/2021-03-19T10:25:03+08:00http://ukccfkn.cn/en/2018/03/12/innovation-joint-efforts-defense-shinsei-electronics-management-visited-eisai-china-headquarter/2021-03-19T10:27:19+08:00http://ukccfkn.cn/en/2018/01/11/eisai-completes-construction-of-oral-solid-dose-production-facility-at-new-suzhou-plant-in-china/2021-03-19T10:29:45+08:00http://ukccfkn.cn/en/2017/12/27/anticancer-agent-lenvatinib-designated-for-priority-review-and-approval-by-china-food-and-drug-administration-for-hepatocellular-carcinoma/2022-03-11T15:35:25+08:00http://ukccfkn.cn/en/2017/12/13/aricept-approved-for-additional-indication-of-severe-alzheimers-disease-in-china/2021-03-19T10:32:37+08:00http://ukccfkn.cn/en/2017/10/31/new-drug-application-of-anticancer-agent-lenvatinib-for-hepatocellular-carcinoma-accepted-in-china/2021-03-19T10:33:24+08:00http://ukccfkn.cn/en/2017/09/29/eisai-presents-results-of-phase-iii-trial-of-lenvima-lenvatinib-in-unresectable-hepatocellular-carcinoma-in-oral-session-at-20th-csco-annual-meeting/2022-03-11T14:32:03+08:00http://ukccfkn.cn/en/2017/09/19/eisai-presents-results-of-phase-iii-clinical-study-of-lenvima-lenvatinib-in-unresectable-hepatocellular-carcinoma-at-11th-ilca-annual-conference/2021-03-19T11:00:42+08:00http://ukccfkn.cn/en/2017/09/15/eisai-china-joins-hands-with-partners-to-kick-off-alzheimers-care-for-the-well-being-of-chinese-families/2021-08-24T17:20:52+08:00http://ukccfkn.cn/en/2017/09/11/eisai-selected-for-fifth-consecutive-year-of-membership-in-dow-jones-sustainability-asia-pacific-index-2017/2021-03-19T11:06:31+08:00http://ukccfkn.cn/en/2017/09/08/conclusion-of-development-collaboration-agreement-for-lenvima-lenvatinib-mesylate-and-opdivo-nivolumab-combination-therapy-for-treatment-of-hepatocellular-carcinoma/2021-03-19T11:08:08+08:00http://ukccfkn.cn/en/2017/09/02/eisai-china-listed-in-2016-china-top-100-pharmaceutical-companies/2021-03-19T11:10:09+08:00http://ukccfkn.cn/en/2017/07/27/u-s-fda-approves-additional-use-of-antiepileptic-drug-fycompa-as-monotherapy-for-partial-onset-seizures/2021-03-19T11:12:03+08:00http://ukccfkn.cn/en/2017/07/25/eisai-submits-simultaneous-applications-in-the-united-states-and-europe-for-lenvatinib-in-hepatocellular-carcinoma/2021-03-19T11:13:14+08:00http://ukccfkn.cn/en/2017/06/05/eisai-to-present-results-of-phase-iii-trial-of-lenvima-lenvatinib-as-first-line-treatment-for-unresectable-hepatocellular-carcinoma-in-oral-session-at-53rd-asco-annual-meeting/2021-03-19T11:15:49+08:00http://ukccfkn.cn/en/2017/06/05/eisai-to-present-results-of-phase-ib-ii-study-of-anticancer-agent-lenvima-lenvatinib-in-combination-with-anti-pd-1-antibody-pembrolizumab-for-the-treatment-of-endometrial-carcinoma-at-53rd-asc/2021-03-19T11:17:08+08:00http://ukccfkn.cn/en/2017/06/01/initiatives-for-developing-new-medicines-for-neglected-tropical-diseases-and-malaria/2021-03-19T11:21:30+08:00http://ukccfkn.cn/en/2017/04/19/eisai-chinas-total-1-98-million-rmb-worth-of-medicine-donation-to-health-to-countryside-activity-for-four-consecutive-years/2021-03-19T11:23:14+08:00http://ukccfkn.cn/en/2017/04/11/speedy-care-to-relieve-fatigue-eisai-to-launch-chocola-bb-gold-richhighest-combination-of-active-ingredients-in-chocola-bb-series-easy-to-drink-bergamot-flavor/2021-03-19T11:26:01+08:00http://ukccfkn.cn/en/2017/04/05/eisai-and-meiji-enter-into-licensing-agreement-concerning-parkinsons-disease-drug-safinamide-in-japan-and-asia/2022-03-11T15:06:56+08:00http://ukccfkn.cn/en/2017/04/05/eisai-presents-data-of-mechanisms-of-action-relating-to-tumor-immune-response-regarding-combination-of-anticancer-agent-lenvatinib-with-anti-pd-1-antibody-at-aacr-108th-annual-meeting/2021-03-19T11:28:48+08:00http://ukccfkn.cn/en/2017/03/28/german-federal-joint-committee-g-ba-confirms-additional-benefit-of-anticancer-agent-kisplyx-lenvatinib-mesylate-in-treatment-of-advanced-renal-cell-carcinoma/2021-03-19T11:30:57+08:00http://ukccfkn.cn/en/2017/02/16/eisai-enters-into-marketing-and-distribution-agreement-with-orion-concerning-parkinsons-disease-drugs-in-china/2021-03-19T11:32:08+08:00http://ukccfkn.cn/en/2017/01/05/eisai-acquires-all-global-development-and-marketing-rights-for-chronic-weight-management-treatment-lorcaserin/2022-03-11T15:08:43+08:00http://ukccfkn.cn/en/2016/12/19/anticancer-agent-treakisym-approved-in-japan-for-additional-indication-as-first-line-treatment-for-low-grade-b-cell-non-hodgkin%e2%80%b2s-lymphoma-and-mantle-cell-lymphoma/2021-03-19T11:34:18+08:00http://ukccfkn.cn/en/2016/12/12/interim-analysis-of-phase-ib-ii-study-of-eribulin-and-pembrolizumab-combination-regimen-in-metastatic-triple-negative-breast-cancer-presented-at-san-antonio-breast-cancer-symposium/2021-03-19T11:35:13+08:00http://ukccfkn.cn/en/2016/12/12/eisai-presents-latest-data-on-bace-inhibitor-elenbecestat%ef%bc%88e2609%ef%bc%89at-9th-clinical-trials-on-alzheimers-disease/2021-03-19T13:10:54+08:00http://ukccfkn.cn/en/2016/11/30/eisai-to-present-latest-data-on-eribulin-at-39th-annual-san-antonio-breast-cancer-symposium/2021-03-19T13:12:21+08:00http://ukccfkn.cn/en/2016/11/30/eisai-to-present-latest-data-on-perampanel-and-rufinamide-at-70th-american-epilepsy-society-annual-meeting/2021-03-19T13:13:19+08:00http://ukccfkn.cn/en/2016/11/14/statement-regarding-the-results-of-the-access-to-medicine-index-2016/2021-03-19T13:15:14+08:00http://ukccfkn.cn/en/2016/11/04/u-k-nice-recommends-anticancer-agent-halaven-as-treatment-for-advanced-breast-cancer/2021-03-19T13:16:38+08:00http://ukccfkn.cn/en/2016/10/20/ceo-naito-selected-among-the-best-performing-ceos-in-the-world-by-harvard-business-review/2021-03-19T13:22:55+08:00http://ukccfkn.cn/en/2016/10/17/eisai-to-officially-launch-chocola-bb-rich-ceramide-in-stores-japan/2021-03-19T13:28:20+08:00http://ukccfkn.cn/en/2016/10/04/belviq-xr-a-new-once-daily-formulation-of-belviq-for-chronic-weight-management-now-available-in-the-united-states/2021-03-19T13:32:48+08:00http://ukccfkn.cn/en/2016/09/30/eisai-to-initiate-phase-iii-clinical-study-of-anticancer-agent-lenvatinib-as-potential-first-line-therapy-for-advanced-renal-cell-carcinoma/2021-03-19T13:34:12+08:00http://ukccfkn.cn/en/2016/09/29/eisai-to-present-latest-data-on-lenvatinib-and-eribulin-at-esmo-congress-2016/2021-03-19T13:35:39+08:00http://ukccfkn.cn/en/2016/09/15/eisai-receives-license-for-new-indication-for-anticancer-agent-kisplyx-%e2%96%bc-lenvatinib-mesylate-for-treatment-of-advanced-renal-cell-carcinoma/2021-03-19T13:44:23+08:00http://ukccfkn.cn/en/2016/09/14/eisai-selected-for-fourth-consecutive-year-of-membership-in-dow-jones-sustainability-asia-pacific-index-2016/2021-03-19T13:45:57+08:00http://ukccfkn.cn/en/2016/09/04/not-only-for-classics-a-record-on-eisai-china-2016-peripheral-neuropathy-forum/2021-03-19T13:47:46+08:00http://ukccfkn.cn/en/2016/08/23/eisai-to-launch-chocola-bb-mouth-ulcer-repair-shot-first-mouth-ulcer-spray-for-the-chocola-bb-brand/2021-03-19T13:49:12+08:00http://ukccfkn.cn/en/2016/08/09/u-s-fda-confirms-sufficient-data-to-advance-investigational-bace-inhibitor-e2609-for-treatment-of-early-alzheimers-disease-to-phase-iii-planning-underway-towards-phase-iii-study-initiation-i/2021-03-19T13:51:23+08:00http://ukccfkn.cn/en/2016/07/22/eisai-receives-positive-chmp-opinion-on-new-indication-for-anticancer-agent-lenvatinib-in-combination-with-everolimus-for-treatment-of-advanced-renal-cell-carcinoma/2021-03-19T13:52:52+08:00http://ukccfkn.cn/en/2016/07/19/u-s-fda-approves-belviq-xr-a-once-daily-formulation-of-lorcaserin-for-chronic-weight-management/2021-03-19T13:54:04+08:00http://ukccfkn.cn/en/2016/07/15/antiobesity-agent-venespri-lorcaserin-approved-in-mexico-first-country-in-latin-america-to-approve-lorcaserin/2022-03-11T15:09:56+08:00http://ukccfkn.cn/en/2016/07/11/eisai-china-trip-to-guizhou-record-on-guizhou-green-expo-big-health-pharmaceutical-industry-fair-and-summit/2021-03-19T13:56:23+08:00http://ukccfkn.cn/en/2016/06/27/eisai-china-participated-in-the-2nd-annual-scientific-session-of-chinese-stroke-association-csa-and-tiantan-international-stroke-conference-tisc-focus-on-post-stroke-cognitive-impairment-psci/2021-03-19T13:58:25+08:00http://ukccfkn.cn/en/2016/06/01/osd-facility-relocation-groundbreaking-ceremony-of-eisai-china/2021-03-19T13:59:51+08:00http://ukccfkn.cn/en/2016/05/20/eisai-china-donates-medicines-worth-144000-yuan-to-the-health-for-rural-areas-program-for-three-consecutive-years/2021-03-19T14:01:17+08:00http://ukccfkn.cn/en/2016/04/05/eisai-receives-positive-chmp-opinion-on-new-indication-for-anticancer-agent-halaven-for-treatment-of-advanced-liposarcoma/2021-03-19T14:02:12+08:00http://ukccfkn.cn/en/2015/12/01/eisai-to-acquire-chinese-generic-pharmaceutical-company-liaoning-tianyi-biological-pharmaceutical-co-ltd/2021-03-31T11:39:59+08:00http://ukccfkn.cn/en/2014/09/19/eisai-presenting-the-first-gifts-to-students-of-yunzhou-central-primary-school-in-chicheng-county-after-they-came-back-to-school/2021-03-31T11:39:32+08:00http://ukccfkn.cn/en/2014/09/19/eisai-donating-medical-supplies-and-cashes-valued-rmb-600000-to-ludian-earthquake-stricken-areas-in-yunnan/2021-03-31T11:39:05+08:00http://ukccfkn.cn/en/2013/12/02/meet-you-on-wednesdays-platform/2021-03-31T11:38:27+08:00http://ukccfkn.cn/en/2013/12/02/we-orthopedics/2021-03-31T11:37:56+08:00http://ukccfkn.cn/en/2013/07/16/osteoporosis-care-for-doctors-kick-off-meeting/2021-03-31T11:37:26+08:00http://ukccfkn.cn/en/2012/09/12/the-opening-ceremony-of-eisai-youth-elite-training-camp-and-award-ceremony-of-eisai-scholarship-2011/2021-03-31T11:36:59+08:00http://ukccfkn.cn/en/2012/09/11/2012-eisai-campus-recruitment/2021-03-31T13:11:01+08:00http://ukccfkn.cn/en/2011/12/28/2011-eisai-scholarshipaward-ceremony-held-at-suzhou-university/2021-04-07T22:06:24+08:00http://ukccfkn.cn/en/2011/11/22/2011-eisai-scholarship-award-ceremony-held-at-zhongshan-university/2021-03-31T11:34:41+08:00http://ukccfkn.cn/en/2011/09/30/2011-eisai-scholarship-award-ceremony-held-at-suzhou-pharmaceutical-technology-school/2021-03-19T15:33:10+08:00http://ukccfkn.cn/en/2011/06/14/eci-formally-launched-its-official-website/2021-03-19T15:30:58+08:00http://ukccfkn.cn/en/2011/03/04/scholarship-awarded-by-eisai-china-inc-at-zhongshan-university/2021-03-19T15:30:15+08:00http://ukccfkn.cn/en/2010/12/29/eisai-scholarship-award-ceremony-in-suzhou-university/2021-03-19T15:29:49+08:00http://ukccfkn.cn/en/2010/09/29/eisai-scholarship-award-ceremony-in-suzhou-pharmaceutical-technology-school/2021-03-19T15:28:37+08:00http://ukccfkn.cn/en/2010/09/11/2010-yellow-handkerchief-love-action-kicks-off/2021-03-19T15:27:54+08:00http://ukccfkn.cn/en/2010/04/19/eisai-china-donated-antibiotics-drugs-to-yushu/2021-03-19T15:27:26+08:00http://ukccfkn.cn/en/2021/03/30/european-medicines-agency-accepts-the-marketing-authorisation-applications-for-two-additional-indications-of-anti-cancer-agent-lenvatinib-in-combination-with-pembrolizumab-as-a-treatment-for-advanced/2021-04-13T14:52:43+08:00http://ukccfkn.cn/en/2021/03/31/kyorin-and-eisai-enter-into-license-agreement-concerning-the-development-and-marketing-of-vibegron-a-treatment-for-overactive-bladder-in-four-asean-countries/2022-03-11T12:16:12+08:00http://ukccfkn.cn/en/2021/03/31/application-submitted-for-additional-indication-of-anti-cancer-agent-lenvima-in-combination-with-keytruda-as-a-treatment-for-advanced-renal-cell-carcinoma-in-japan/2021-04-13T17:53:05+08:00http://ukccfkn.cn/en/2021/06/07/new-data-on-lenvima-lenvatinib-plus-keytruda-pembrolizumab-versus-sunitinib-in-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-from-pivotal-phase-3-clear-keynote-5/2021-07-05T13:33:07+08:00http://ukccfkn.cn/en/2021/06/18/eisai-and-bristol-myers-squibb-enter-into-global-strategic-collaboration-for-eisais-morab-202-antibody-drug-conjugate/2022-03-11T13:51:13+08:00http://ukccfkn.cn/en/2021/07/09/fda-approves-updated-aduhelm-prescribing-information-to-emphasize-population-studied-in-clinical-trials-aduhelm-should-be-initiated-in-patients-with-mild-cognitive-impairment-due-to-alzheim/2021-07-09T15:52:49+08:00http://ukccfkn.cn/en/2021/06/29/shanghai-tennry-and-eisai-china-inc-reached-a-strategic-cooperation-in-the-chinese-market/2021-07-12T11:18:58+08:00http://ukccfkn.cn/en/2021/05/06/eisai-and-merck-co-inc-kenilworth-n-j-u-s-a-receive-priority-review-from-fda-for-lenvima-lenvatinib-plus-keytruda-pembrolizumab-applications-for-advanced-renal-cell-carci/2021-07-13T15:12:54+08:00http://ukccfkn.cn/en/2021/06/23/eisai-and-merck-co-inc-kenilworth-n-j-u-s-a-receive-priority-review-from-fda-for-lenvima-lenvatinib-plus-keytruda-pembrolizumab-applications-for-advanced-renal-cell-carci-2/2021-07-13T15:44:56+08:00http://ukccfkn.cn/en/2021/07/21/eisai-to-present-latest-data-on-pipeline-assets-in-the-area-of-alzheimers-disease-and-dementia-at-the-alzheimers-association-international-conference-aaic-2021/2021-07-27T17:17:39+08:00http://ukccfkn.cn/en/2021/08/05/eisai-receives-award-for-excellence-in-corporate-communications-at-the-37th-corporate-communications-awards/2021-08-06T17:08:10+08:00http://ukccfkn.cn/en/2021/09/14/eisai-to-present-abstracts-on-oncology-products-and-pipeline-at-esmo-virtual-congress-2021/2021-09-15T15:15:30+08:00http://ukccfkn.cn/en/2021/11/01/the-creb-binding-protein-cbp-%ce%b2-catenin-inhibitor-e7386-co-created-by-eisai-and-prism-biolab-achieved-the-clinical-poc-proof-of-concept/2021-11-01T18:44:33+08:00http://ukccfkn.cn/en/2021/10/18/eisai-and-merck-co-inc-kenilworth-n-j-u-s-a-receive-positive-eu-chmp-opinions-for-lenvima-lenvatinib-plus-keytruda-pembrolizumab-in-two-different-types-of-cancer/2021-11-03T15:00:44+08:00http://ukccfkn.cn/en/2021/11/19/eisai-selected-for-membership-in-dow-jones-sustainability-asia-pacific-index-2021-for-eighth-time/2021-11-22T16:14:47+08:00http://ukccfkn.cn/en/2021/11/18/eisai-receives-the-most-liked-ir-award-at-the-2021-ir-award/2021-11-22T16:35:17+08:00http://ukccfkn.cn/en/2021/11/11/eisai-presents-late-breaker-updates-on-lecanemab-clinical-biomarker-and-safety-data-from-phase-2b-study-core-and-open-label-extension-across-five-years-at-clinical-trials-on-alzheimers-disea/2021-11-22T17:09:18+08:00http://ukccfkn.cn/en/2021/12/24/investigational-alzheimers-disease-therapy-lecanemab-granted-fda-fast-track-designation/2021-12-28T14:05:56+08:00http://ukccfkn.cn/en/2021/12/20/eisai-enters-into-commercialization-and-distribution-agreement-with-gilead-for-jak-inhibitor-filgotinib-in-asia/2022-03-11T12:41:11+08:00http://ukccfkn.cn/en/2021/11/30/eisai-and-fcnt-enter-into-business-alliance-aiming-to-support-people-living-with-dementia-and-to-prevent-dementia/2021-12-28T16:08:53+08:00http://ukccfkn.cn/en/2021/11/04/eisai-presents-new-data-on-the-relationship-between-clinical-biomarker-and-safety-outcomes-from-the-lecanemab-phase-2b-study-for-early-alzheimers-disease-in-late-breakers-and-pipeline-update/2021-12-28T16:32:11+08:00http://ukccfkn.cn/en/2021/11/09/dian-tu-selects-lecanemab-as-background-anti-amyloid-therapy-in-clinical-trial-evaluating-investigational-therapy-targeting-tau-for-dominantly-inherited-alzheimers-disease/2021-12-28T16:57:29+08:00http://ukccfkn.cn/en/2021/12/24/lenvima-lenvatinib-plus-keytruda-pembrolizumab-approved-in-japan-for-patients-with-unresectable-advanced-or-recurrent-endometrial-carcinoma-that-progressed-after-cancer-chemotherapy/2022-01-11T14:57:10+08:00http://ukccfkn.cn/en/2021/11/30/eisai-to-present-latest-data-on-perampanel-and-e2730-at-the-75th-american-epilepsy-society-annual-meeting/2022-01-11T15:17:29+08:00http://ukccfkn.cn/en/2022/02/01/eisai-receives-the-tokyo-governor-prize-for-corporate-governance-of-the-year-2021/2022-02-18T14:03:32+08:00http://ukccfkn.cn/en/2022/01/28/eisai-announces-results-and-continued-support-of-initiatives-for-elimination-of-neglected-tropical-diseases/2022-02-18T14:18:29+08:00http://ukccfkn.cn/en/2022/01/17/eisai-to-present-abstracts-on-lenvatinib-at-2022-asco-gastrointestinal-cancers-symposium/2022-02-18T14:32:25+08:00http://ukccfkn.cn/en/2022/01/06/eisai-enters-into-exclusive-licensing-agreement-with-roivant-concerning-investigational-anticancer-agent-h3b-8800a-splicing-modulator/2022-02-18T16:08:43+08:00http://ukccfkn.cn/en/2021/11/29/european-commission-approves-lenvima-lenvatinib-plus-keytruda-pembrolizumab-as-first-line-treatment-for-adult-patients-with-advanced-renal-cell-carcinoma/2022-02-18T16:18:37+08:00http://ukccfkn.cn/en/2021/11/29/european-commission-approves-lenvima-lenvatinib-plus-keytruda-pembrolizumab-for-patients-with-certain-types-of-endometrial-carcinoma/2022-02-18T16:26:38+08:00http://ukccfkn.cn/en/2021/11/12/introduction-of-first-of-a-kind-plasma-based-biomarker-screening-to-facilitate-identification-of-subjects-for-phase-3-ahead-3-45-trial-presented-at-clinical-trials-on-alzheimers-disease-ctad/2022-02-21T15:32:32+08:00http://ukccfkn.cn/en/2021/11/12/eisai-presents-new-analysis-of-lecanemab-clinical-efficacy-results-from-phase-2b-study-at-clinical-trials-on-alzheimers-disease-ctad-conference/2022-02-21T15:49:25+08:00http://ukccfkn.cn/en/2022/04/01/eisai-announcesacquisition-of-arteryexshares-making-arteryexa-subsidiary-to-strengthen-and-rapidly-expand-the-foundation-of-its-digital-solution-business/2022-04-01T16:26:21+08:00http://ukccfkn.cn/en/2022/07/26/eisai-listed-for-21st-consectutive-year-in-ftse4good-index-series-an-index-for-socially-responsible-investment/2022-07-28T13:44:49+08:00http://ukccfkn.cn/en/2022/07/26/eisai-to-present-the-latest-lecanemab-data-including-aria-e-and-subcutaneous-formulation-and-other-alzheimers-disease-research-at-the-alzheimers-association-international-conferenc/2022-07-28T16:28:39+08:00http://ukccfkn.cn/en/2022/08/09/eisai-and-lifenet-enter-into-capital-and-business-alliance-agreement-aimed-at-building-ecosystem-to-reduce-burden-of-medical-and-nursing-care/2022-08-11T11:14:49+08:00http://ukccfkn.cn/en/2022/10/04/eisai-completes-construction-of-its-new-injection-research-building-at-kawashima-industrial-park-in-japan/2022-10-28T11:24:01+08:00http://ukccfkn.cn/en/2022/09/26/metoject-subcutaneous-injection-syringe-methotrexate-approved-in-japan-for-rheumatoid-arthritis/2022-10-28T11:41:43+08:00http://ukccfkn.cn/en/2022/09/12/eisai-presents-results-of-post-hoc-analysis-of-eribulin-mesylate-halaven-at-the-european-society-for-medical-oncology-esmo-congress-2022/2022-10-28T12:02:46+08:00http://ukccfkn.cn/en/2022/09/12/eisai-and-merck-co-inc-rahway-nj-usa-present-results-from-phase-3-leap-002-trial-evaluating-lenvima-lenvatinib-plus-keytruda-pembrolizumab-versus-lenvima-monotherapy-in-pat/2022-10-28T13:54:50+08:00http://ukccfkn.cn/en/2022/09/28/lecanemab-confirmatory-phase-3-clarity-ad-study-met-primary-endpoint-showing-highly-statistically-significant-reduction-of-clinical-decline-in-large-global-clinical-study-of-1795-participants-with-e/2022-10-28T15:50:29+08:00http://ukccfkn.cn/en/2022/10/31/eisai-announces-plans-to-submit-application-for-partial-change-to-label-for-dosage-and-administration-of-aricept-for-treatment-of-dementia-with-lewy-bodies-based-on-results-of-drug-reexamination/2022-11-04T15:06:53+08:00http://ukccfkn.cn/en/2022/11/02/eisai-satisfies-all-case-study-requirement-for-antiepileptic-agent-inovelon/2022-11-04T15:24:01+08:00http://ukccfkn.cn/en/2022/11/30/eisai-presents-full-results-of-lecanemab-phase-3-confirmatory-clarity-ad-study-for-early-alzheimers-disease-at-clinical-trials-on-alzheimers-disease-ctad-conference/2022-11-30T14:05:25+08:00http://ukccfkn.cn/en/2022/11/21/eisai-to-present-full-findings-from-lecanemab-confirmatory-phase-3-clinical-trial-clarity-ad-and-other-alzheimers-disease-research-at-the-15th-clinical-trials-on-alzheimers-disease-ctad/2022-11-30T15:27:48+08:00http://ukccfkn.cn/en/2022/08/30/supplementary-new-drug-application-submitted-in-japan-for-antiepileptic-drug-fycompa-injection-formulation-as-a-new-route-of-administration/2022-11-30T16:07:29+08:00http://ukccfkn.cn/en/2022/08/24/eisai-inc-collaborates-with-c2n-to-build-awareness-and-real-world-evidence-for-blood-based-assays-in-the-diagnosis-of-people-living-with-cognitive-impairment-in-clinical-practice-in-the-u-s-outside/2022-11-30T16:13:35+08:00http://ukccfkn.cn/en/2022/06/22/eisai-publishes-potential-economic-value-of-investigational-lecanemab-in-peer-reviewed-neurology-and-therapy-journal/2022-11-30T16:29:28+08:00http://ukccfkn.cn/en/2022/12/01/eisai-to-present-preclinical-and-clinical-research-on-eribulin-at-the-2022-san-antonio-breast-cancer-symposium/2022-12-20T15:12:54+08:00http://ukccfkn.cn/en/2022/12/15/eisai-and-washington-university-school-of-medicine-in-st-louis-enter-into-comprehensive-research-collaboration-agreement-aiming-to-create-new-therapies-for-neurodegenerative-diseases/2022-12-20T15:27:25+08:00http://ukccfkn.cn/en/2022/12/20/eisai-to-divest-rights-for-anti-epileptic-drug-fycompa-perampanel-ciii-in-united-states-to-catalyst-pharmaceuticals/2022-12-20T16:00:19+08:00http://ukccfkn.cn/en/2022/12/22/astellas-eisai-daiichi-sankyo-and-takeda-agree-to-collaborate-to-reduce-environmental-burden-in-the-field-of-pharmaceutical-packaging/2022-12-22T16:05:14+08:00http://ukccfkn.cn/en/2022/12/23/eisai-initiates-bla-submission-of-data-for-lecanemab-in-china/2022-12-23T10:16:57+08:00http://ukccfkn.cn/en/2023/01/07/fda-approves-leqembi-lecanemab-irmb-under-the-accelerated-approval-pathway-for-the-treatment-of-alzheimers-disease/2023-01-09T16:28:36+08:00http://ukccfkn.cn/en/2023/01/18/6400/2023-01-28T15:12:17+08:00http://ukccfkn.cn/en/2023/01/30/lecanemab-receives-priority-review-status-in-japan/2023-02-22T16:37:15+08:00http://ukccfkn.cn/en/2023/02/28/biologics-license-application-for-lecanemab-designated-for-priority-review-by-china-national-medical-products-administration/2023-03-13T17:19:14+08:00http://ukccfkn.cn/en/2023/03/06/fda-accepts-eisais-filing-of-a-supplemental-biologics-license-application-and-grants-priority-review-for-traditional-approval-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheim/2023-03-22T16:14:33+08:00http://ukccfkn.cn/en/2023/03/09/eisai-certified-as-a-2023-health-and-productivity-management-outstanding-organization-white-500/2023-05-04T11:21:46+08:00http://ukccfkn.cn/en/2023/03/10/eisai-receives-the-basic-achievement-grand-prize-at-the-2023-j-win-diversity-award/2023-05-04T11:50:03+08:00http://ukccfkn.cn/en/2023/03/23/eisai-to-present-new-lecanemab-data-including-research-evaluating-safety-profile-clinical-outcomes-and-quality-of-life-measures-as-well-as-other-important-alzheimers-disease-research-at-t/2023-05-04T12:17:50+08:00http://ukccfkn.cn/en/2023/04/06/eisai-completes-a-major-renovation-of-tsukuba-research-laboratories/2023-05-04T12:33:50+08:00http://ukccfkn.cn/en/2023/03/24/eisai-to-present-research-from-oncology-portfolio-at-the-society-of-gynecologic-oncology-sgo-2023-annual-meeting-on-womens-cancer/2023-05-10T11:20:46+08:00http://ukccfkn.cn/en/2023/05/08/eisai-enters-into-joint-development-agreement-with-blissbio-for-antibody-drug-conjugate-bb-1701-with-option-rights-for-strategic-collaboration/2023-05-10T11:19:59+08:00http://ukccfkn.cn/en/2023/05/11/feng-yanhui-president-of-eisai-china-visited-sinopharm-holding-henan/2023-05-17T16:57:41+08:00http://ukccfkn.cn/en/2023/05/16/health-canada-accepts-new-drug-submission-for-lecanemab-as-treatment-for-early-alzheimers-disease/2023-05-17T17:14:15+08:00http://ukccfkn.cn/en/2023/05/22/eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-great-britain/2023-05-23T10:13:12+08:00http://ukccfkn.cn/en/2023/05/24/eisai-delivers-new-data-and-highlights-continued-progress-of-oncology-portfolio-and-pipeline-at-asco-2023/2023-05-26T13:22:14+08:00http://ukccfkn.cn/en/2023/05/26/lenvima-lenvatinib-plus-keytruda-pembrolizumab-demonstrates-long-term-durable-survival-benefit-versus-sunitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma/2023-05-26T13:29:25+08:00http://ukccfkn.cn/en/2023/05/25/eisais-initiatives-for-developing-new-medicines-for-neglected-tropical-diseases-and-malaria-and-commitment-for-funding-to-the-3rd-phase-of-global-health-innovative-technology-fund-activities/2023-05-30T11:53:50+08:00http://ukccfkn.cn/en/2023/06/02/eisai-to-present-latest-data-on-lemborexant-at-the-37th-annual-sleep-2023-meeting/2023-06-02T14:58:46+08:00http://ukccfkn.cn/en/2023/06/10/fda-advisory-committee-votes-unanimously-to-confirm-the-clinical-benefit-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimers-disease/2023-06-12T10:45:07+08:00http://ukccfkn.cn/en/2023/04/14/lecturer-group-on-gastrointestinal-mucosa-established-in-beijing/2023-06-25T14:29:02+08:00http://ukccfkn.cn/en/2023/06/06/eisai-china-suzhou-plant-successfully-passed-the-energy-management-system-certification/2023-06-25T14:34:37+08:00http://ukccfkn.cn/en/2023/06/22/eisais-nouknow-will-continue-to-be-utilized-for-brain-health-assessment-as-part-of-the-fy2023-dementia-examination-project-by-tokyo-bunkyo-city/2023-06-26T11:46:25+08:00http://ukccfkn.cn/en/2023/06/26/tencent-healthcare-and-eisai-china-deepen-strategic-partnership-to-create-new-paradigm-of-digital-innovation/2023-06-27T10:41:54+08:00http://ukccfkn.cn/en/2023/06/29/new-neurii-research-collaboration-between-eisai-gates-ventures-health-data-research-uk-lifearc-and-the-university-of-edinburgh-to-develop-digital-solutions-for-dementia-is-announced/2023-06-30T11:51:02+08:00http://ukccfkn.cn/en/2023/07/07/fda-grants-traditional-approval-for-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimers-disease/2023-07-17T10:40:39+08:00http://ukccfkn.cn/en/2023/07/12/eisai-to-present-the-latest-alzheimers-disease-pipeline-and-research-including-lecanemab-and-anti-mtbr-tau-antibody-e2814-at-the-alzheimers-association-international-conference-aa/2023-07-17T11:02:20+08:00http://ukccfkn.cn/en/2023/08/04/eisai-listed-for-22nd-consectutive-year-in-ftse4good-index-series-an-index-for-socially-responsible-investment/2023-08-07T15:08:56+08:00http://ukccfkn.cn/en/2023/08/21/results-of-todays-discussion-on-lecanemab-at-japans-first-committee-on-new-drugs-of-the-pharmaceutical-affairs-and-food-sanitation-council/2023-08-23T18:12:20+08:00http://ukccfkn.cn/en/2023/09/12/eisai-establishes-theoria-technologies-co-ltd-a-new-digital-business-company-to-build-a-dementia-ecosystem/2023-09-13T16:12:48+08:00http://ukccfkn.cn/en/2023/09/25/leqembi-intravenous-infusion-lecanemab-approved-for-the-treatment-of-alzheimers-disease-in-japan/2023-09-26T10:42:57+08:00http://ukccfkn.cn/en/2023/10/11/eisai-to-present-research-from-oncology-portfolio-and-pipeline-at-esmo-congress-2023/2023-10-11T16:57:52+08:00http://ukccfkn.cn/en/2023/10/16/eisai-to-present-new-data-from-leqembi-lecanemab-irmb-phase-3-clarity-ad-study-and-other-alzheimers-disease-pipeline-research-at-the-clinical-trials-on-alzheimers-disease-ctad-con/2023-10-16T15:49:48+08:00http://ukccfkn.cn/en/2023/10/25/leqembi-lecanemab-irmb-named-one-of-times-best-inventions-of-2023/2023-10-25T11:01:22+08:00http://ukccfkn.cn/en/2023/11/16/eisai-named-as-greatest-ir-improvement-premium-company-and-best-continual-ir-efforts-premium-company-at-the-japan-investor-relations-association-30th-anniversary-co/2023-11-21T17:20:38+08:00http://ukccfkn.cn/en/2023/11/20/leqembi-wins-best-new-drug-and-clinical-advance-of-the-year-at-the-scrip-awards-2023/2023-11-21T17:28:19+08:00http://ukccfkn.cn/en/2023/12/13/leqembi-intravenous-infusion-lecanemab-for-the-treatment-of-alzheimers-disease-to-be-launched-in-japan-on-december-20/2023-12-27T11:15:10+08:00http://ukccfkn.cn/en/2023/12/18/eisai-submits-marketing-authorization-application-in-japan-for-anticancer-agent-tasurgratinib-for-biliary-tract-cancer-with-fgfr2-gene-fusion/2023-12-27T11:46:08+08:00http://ukccfkn.cn/en/2024/01/17/eisai-listed-as-a-global-100-most-sustainable-corporation-for-the-eighth-time/2024-01-18T16:29:02+08:00http://ukccfkn.cn/en/2024/02/01/eisai-submits-new-drug-application-for-mecobalamin-ultrahigh-dose-formulation-in-japan-for-the-indication-of-amyotrophic-lateral-sclerosis/2024-02-01T11:24:25+08:00http://ukccfkn.cn/en/2024/04/18/antiepileptic-drug-fycompa-injection-formulation-launched-in-japan/2024-04-18T15:43:49+08:00http://ukccfkn.cn/en/2024/03/28/discovery-research-on-dual-orexin-receptor-antagonist-lemborexant-honored-with-psj-award-for-drug-research-and-development-2024/2024-04-18T15:49:24+08:00http://ukccfkn.cn/en/2024/05/27/leqembi-lecanemab-approved-for-the-treatment-of-alzheimers-disease-in-south-korea/2024-05-29T14:24:22+08:00http://ukccfkn.cn/en/2024/05/15/eisai-initiates-rolling-biologics-license-application-to-us-fda-for-leqembi-lecanemabirmb-for-subcutaneous-maintenance-dosing-for-the-treatment-of-early-alzheimers-disease-under-the-f/2024-05-29T14:32:10+08:00http://ukccfkn.cn/en/2024/07/16/eisai-enters-into-license-agreement-for-fosravuconazole-in-asia-oceania-with-sato-pharma/2024-07-17T10:35:47+08:00http://ukccfkn.cn/en/2024/08/14/leqembi-lecanemab-approved-for-the-treatment-of-alzheimers-disease-in-the-united-arab-emirates/2024-08-15T09:51:41+08:00http://ukccfkn.cn/en/2024/08/06/update-regarding-the-regulatory-status-of-leqembi-subcutaneous-formulation/2024-08-15T09:56:45+08:00http://ukccfkn.cn/en/2024/08/22/leqembi-lecanemab-authorized-for-early-alzheimers-disease-in-great-britain/2024-08-23T11:02:14+08:00